Introduction
Human parainfluenza virus type 1 (hPIV-1) is an important pathogen, causing respiratory tract infection in children. HPIV-1 was originally isolated in 1958 (Chanock et al., 1958) , and was found to have the same characteristics as the other paramyxoviruses, such as haemagglutinating (Chanock et al., 1958) , neuraminidase (Kessler et al., 1977) and fusion activities (Nakamura & Homma, 1974) . It has been shown that hPIV-1 and Sendal virus (SV) belong to the same group within the paramyxovirus genus (Chanock & Macintosh, 1990) , and hPIV-1 has been reported to be antigenically related to SV, as shown by cross-reactivity of polyclonal antisera (Ito et al., 1987) . The polypeptides of hPIV-1 were identified by using anti-SV antisera (Yoshida et al., 1985) .
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The nucleotide sequences of the haemagglutininneuraminidase (HN) (Gorman et al., 1990; Matsuoka et al., 1990) , fusion (F) (Merson et al., 1988) and nucleocapsid (NP) Lyn et al., 1991) , and phospho (P) proteins of hPIV-1 have recently been reported. Sequence analyses have shown that there is significant amino acid similarity between hPIV-1 and SV HN (72~), F (68~), NP (81.3~) and P (53~) proteins. However, antigenic comparison of hPIV-1 and SV HN using monoclonal antibodies (MAbs) against SV indicates limited conservation of epitopes (Gorman et al., 1990) . In addition, only limited antigenic similarity between hPIV-1 and SV NP by using anti-NP MAbs has been reported (Lyn et al., 1991) .
To study further the antigenic relationship between hPIV-1 and SV, and the antigenic diversity of clinical hPIV-1 isolates, we prepared a large number of MAbs against hPIV-1 and analysed the antigenicity of hPIV-1 and SV using these MAbs and anti-SV MAbs characterized previously (Orvell & Grandien, 1982; Orvell & Kristensson, 1985; Orvell etaL, 1986; Vidal etal., 1988) . The antigenic relationships between the F and P proteins of hPIV-1 and SV were first analysed using the MAbs. The results indicated that hPIV-I and SV have limited similarities. Antigenic variation between clinical hPIV-1 isolates was also revealed, especially HN.
Methods
Cells and viruses. Primary monkey kidney (PMK) and LLCMK z cells were grown in Eagle's MEM supplemented with 5% calf serum. HPIV-1 (59-34 strain), isolated in Tokyo in 1965 by Dr F. Nishikawa (Nippon Medical School, Tokyo, Japan), was used as the prototype virus. The clinical isolates of hPIV-1 were kindly given by Dr F. Nishikawa and Dr K. Nakamura (Nagano Prefectural Institute of Environmental Pollution and Public Health, Nagano, Japan). SV [strains Z., Fushimi and Nagoya (W)] were also used.
Mice. Male BALB/c mice were used for immunization with hPIV-1, and were also used for ascites preparation.
Production and isolation of hybridoma cell lines.
Immunization of mice with hPIV-1 and fusion of mouse spleen cells with SP2/0-AG-14 myeloma cells were performed as described (Tsurudome et al., 1986 (Tsurudome et al., , 1990 Komada et al., 1989) . Individual wells were screened by ELISA. Cultures of interest were then cloned by soft agar colony formation and amplified, before storage in liquid nitrogen and passage as ascites in mice.
The MAbs against SV (Z strain) characterized previously (Orvell & Grandien, 1982; Orvell & Kristensson, 1985; Orvell et al., 1986; Vidal et al., 1988) were used in the ELISA and neutralization (NT) assay.
ELISA. ELISA was performed as described previously (Tsurudome et al., 1986) . For screening of anti-hPIV-1 hybridoma clones, determination of antibody class and subclass, and determination of cross-reactivity, PMK cells were grown in 96-well microtitre plates and infected with various isolates of hPIV-1 or various SV strains. The infected cells were fixed with 1% formaldehyde solution at appropriate times after infection and used as antigens for ELISA .
Competitive binding assays in ELISA.
Competitive binding assays in ELISA were performed as described by Sato et al. (1985) . For these assays, microtitre plates coated with semi-purified virus were used. The percentage inhibition produced by the competitors was calculated as the absorbance value when inhibition was maximal compared with the absorbance value given by a horseradish peroxidase-conjugated MAb in the absence of any competitor.
Virus purification. PMK and LLCMKE cells were used for growth of hPIV-1. Trypsin (1 Ixg/ml) was added to the serum-free culture medium of hPIV-l-infected LLCMK z cells. Viruses were purified using discontinuous sucrose density gradient centrifugation with a Beckman SW28 rotor. The gradient was composed of 40% and 20% sucrose in TNE buffer (25 mM-Tris-HCl, 50 mM-NaCI and 2 mM-EDTA, pH 7-5).
Radioimmune precipitation assay (RIPA) and SDS-PAGE. RIPA and SDS-PAGE were performed as described previously (Ito et al., 1985) using undiluted culture fluids or 10-fold diluted ascites fluids.
Isotopic labelling of infected cells.
Isotopic labelling of cells was carried out according to the method described previously (Ito et al., 1985) .
NT assay. Serial twofold dilutions of heat-inactivated ascites in MEM were mixed with 100 TCIDs0 of virus suspended in an equal volume of MEM, and incubated at 37 °C for 60 min. Since hPIV-1 induced weak c.p.e., the residual infectivity of the mixture was determined by the haemadsorption method and the NT titre was expressed as the reciprocal of the highest antibody dilution showing 50% haemadsorption inhibition.
Haemagglutinin inhibition (HI), haemolysis inhibition (HLI) and neuraminidase inhibition (NI) assays. HI, HLI and NI tests were performed according to the methods described previously (Tsurudome et al., 1986) using viruses grown on LLCMK2 cells as the antigen. To prepare semi-purified viruses, virus-infected cells were frozen, thawed, sonicated and clarified at 1500 g for 5 rain. Guinea-pig erythrocytes were used for HI and HLI.
Western blot analysis. Western blot analysis was carried out as described previously 
Results

Identification of structural proteins of hPIV-1 using the MAbs directed against Sendai virus (SV) and hPIV-1, and determination of specificity of the anti-hPIV-1 MAbs
The Mrs of the HN and NP proteins of hPIV-1 determined using anti-SV antisera are 74K and 56K, respectively (Yoshida et al., 1985) . We determined the Mr of these proteins by using [35S]methionine-labelled hPIV-l-infected cell lysates and anti-SV MAbs against the HN and NP proteins which also showed reactivity with hPIV-1 (data not shown). The 74K and 56K proteins were also precipitated with anti-hPIV-1 MAbs, which were identified as MAbs against the HN and NP proteins, respectively (Fig. 1, lanes 1 and 2, respectively) . MAbs against the HN protein of hPIV-1 precipitated the 74K glycoprotein from [14C]glucosamine-labelled hPIV-l-infected cell lysates (Fig. 2, lane 1) , and this protein was also precipitated by the MAbs against the HN protein of SV (data not shown).
The 34K protein was precipitated with MAbs against the M protein of SV, indicating that it is the M protein of hPIV-1 (Fig. 1, lane 3) . Of the anti-hPIV-1 MAbs, 19 reacted with the 60K glycoprotein (Fig. 2, lane 2) , which was considered not to be the HN protein or a degradation product of it because no anti-HN MAbs recognized it. In addition, MAbs recognizing the 60K glycoprotein showed HLI activity without HI and NI activities (see below). Sequencing analysis showed that the calculated Mr of the F0 protein without sugar moieties was 60K (Merson et al., 1988) , and therefore the 60K protein detected by S D S -P A G E might be the Fa protein of hPIV-1.
The Mr of the P protein is 83K (Yoshida et aL, 1985) .
This protein was recognized by two hPIV-l-specific M A b s on Western blot analysis (Fig. 3 , lanes 1 and 2) and R I P A with [32p]inorganic phosphate-labelled hPIV-l-infected cell lysates (Fig. 3 , lanes 3 and 4). The N P protein was also found to be a phosphorylated protein (Fig. 3 , lane 5). Thus the structural proteins o f hPIV-1 were identified as P, 83K; H N , 74K; F1, 60K; N P , 56K and M, 34K. On the basis of these results and the biological activities described below, the specificities of the M A b s against hPIV-1 were determined. Two M A b s were directed against the P protein, 24 against the H N protein, 19 against the F protein and 11 against the N P protein.
Topological analysis of antigenic epitopes on the structural proteins
To analyse the antigenic determinants of the P, H N , F and N P proteins topologically, each M A b was labelled with peroxidase for use in a reciprocal competitive binding assay. Each M A b was classified into a group, the members of which recognize the same epitope of a protein (Tables 1, 2 , 3, 4 and 5).
Biological activities of anti-hPIV-1 HN and F protein MAbs
M A b s against the H N and F proteins of hPIV-1 were examined for their NT, HI, H L I and N I activities using the 59-34 and A1426 strains (isolated in Susaka city Nagano in 1988; 88b), and the SV (Z strain) as antigens ( Table 1 ). The A1426 strain was used because it caused c.p.e, in PMK ceils and was isolated recently in a place distant from Tokyo. MAbs against the HN protein could be divided into seven groups according to the results of competitive ELISA (Tables 1 and 3 ). Competition group I identified three epitopes and competition group II two. The grouping by competitive ELISA and biological activities agreed very well (Table 1) . Groups Ia and Ib exhibited high NT, HI and HLI titres, but group Ic showed a low NT titre. In group I, only MAb 8.2.2. A had NT activity against strain A1426. Interestingly, only group II MAbs exhibited NI activity, and they had a low NT titre against the 59-34 prototype strain; some had high NT activity against the A1426 strain. Group III exhibited low NT activity, but had HI activity. Groups IV, V and VI had no HI titre, but they had NT activity against both the 59-34 and A1426 strains ( Table 1) . The crossreactivity in the NT assay (Table 1) and that between the 59-34 and A1426 strains (Table 3 ) agreed well. The MAbs against the HN protein of hPIV-1 had no NT activity against SV (Z strain), though some of them crossreacted in ELISA (Table 3) .
MAbs against the F protein of hPIV-1 could be divided into five groups on the basis of the competitive ELISA. Competition group I identified four epitopes (Tables 2 and 4) , and this grouping agreed well with the biological activities of the MAbs (Table 2 ). The MAbs had neither HI nor NI activitity, but did have HLI activity. Groups Ia, Ib, Ic and II showed NT activity against both the 59-34 and A1426 strains, but groups Id, IV and V exhibited little or no activity against these strains, indicating that the epitopes determining NT activity are well conserved between these two strains, which were isolated in different areas more than 20 years apart. In addition, as described below (Table 4) , the antigenicity of the strains was also conserved. No MAbs could neutralize SV (Z strain), indicating the limited relationship between the glycoproteins of hPIV-1 and SV.
Antigenic diversity of clinical hPIV-1 isolates, and immunological relationships between hPIV-1 and SV revealed by MAbs directed against hPIV-1 or SV
Twenty-three strains of clinical hPIV-1 isolates from Japan, isolated between 1959 to 1989, were examined by using MAbs against hPIV-I or SV (Z strain). The antigenicity was determined in ELISA employing virusinfected PMK cells as antigen.
As shown in Table 3 , MAbs against the HN of hPIV-1 reacted strongly with the isolates isolated in Tokyo from 1959 to 1963, although the isolates from 1962 lacked reactivity with five of the 24 MAbs. MAbs belonging to groups I, III, and VII exhibited relatively low reactivity, especially with the strains which were isolated from 1977 to 1989, indicating that the epitopes on the NH protein changed relatively recently. Strain A1426 (isolated in Susaka city in 1988; 88b), which was neutralized mainly by MAbs from groups II, IV, V and VI showed reactivity with the same MAbs. The MAbs against the HN of hPIV-1 showed limited crossreactivity with the three strains of SV. However, there are a few epitopes common to hPIV-1 and SV. MAb 4.4 cross-reacted with the three strains of SV, and five of seven group II MAbs reacted with the Z strain of SV.
MAbs against the F protein of hPIV-1 recognized almost all strains (Table 4) . Strains isolated in 1962 (62) and 1987 (87g) showed somewhat different reactions (Table 4) . Interestingly, MAbs 3.3, 4.1.1, 9.1 and 1.1.4 showed cross-reactivity with the three strains of SV tested, indicating that the same epitopes on the F protein were conserved in hPIV-1 and SV.
MAbs against NP and the P protein of hPIV-1 also recognized almost all the clinical isolates of hPIV-1 (Table 5) . Interestingly, one MAb (9.5.3) against NP did not recognize the isolates from 1977 to 1989 (Table 5) , just as eight MAbs against HN did not react with the isolates from 1977 to 1989 (Table 3 ). In the 1970s samples, there appear to be some changes in the antigenic site(s) of the HN and NP proteins of hPIV-1. Of 11 MAbs against NP, five had immunological relationships with SV, and these recognized all three strains of SV (Table 5) , just as the four MAbs against the F protein did (Table 4) .
Therefore, although some epitopes on each protein were common to hPIV-1 and SV, these viruses are antigenically distinct.
The isolates of hPIV-1 were also characterized using MAbs against the HN, F, NP, P and M proteins ofSV (Z strain). As is shown in Table 6 , some conserved epitopes on the HN protein were also identified using anti-SV MAbs. MAbs 106, 996, 985 and 298 had neutralizing activity against the hPIV-1 isolates from 1965 (59-34 strain) and 1988 (A1426 strain), indicating that only epitopes involved in the neutralization of both hPIV-1 and SV (Z strain) were conserved on the HN protein of SV. One characteristic feature of the F protein was that there are no epitopes common to SV (Z strain) and hPIV-1 isolates from Susaka and Matsumoto (Table 6 ). The anti-SV F protein MAbs tested had no neutralizing activity against hPIV-1 isolates from 1965 and 1988 (Table 6 ). The NP, P and M proteins ofSV (Z strain) also had epitopes in common with clinical hPIV-1 isolates (Table 7) . The common epitopes were identified independently of the time and place of virus isolation, except for those of the F protein. Interestingly, two clinical isolates of hPIV-1 (87g and 88c) had no epitopes in common with SV (Z strain), and two isolates (62 and 87d) had weak cross-reactivity with MAbs against the M (383) and F (968) proteins of SV, respectively (Tables 7 and 6 ), which indicates that clinical hPIV-1 isolates exist which are distinct from SV (Z strain).
Discussion
In this study, we have reported the isolation and characterization of MAbs against hPIV-1, the identification of the structural proteins of hPIV-1, antigenic variation between clinical hPIV-1 isolates, and the immunological relationship between hPIV-1 and SV.
The structural proteins of hPIV-1 were identified using anti-hPIV-1 MAbs and anti-SV MAbs which cross-reacted with hPIV-1. The Mr of the P and HN proteins was higher than that of the same proteins of SV, whereas the Mr of the NP and F protein was lower. The Mr of the M protein, 34K, differed from the 28K reported by Yoshida et al. (1985) and Gorman et al. (1991) . The M protein of hPIV-1 is composed of 348 amino acids (Miyahara et al., 1992) , as is that of SV, the Mr of which was determined to be 34K by SDS-PAGE (Yoshida et al., 1985) . The difference in Mr of the M protein determined by SDS-PAGE is likely to be due to the conditions of electrophoresis.
The P protein of hPIV-1 was identified by Western blot analysis using purified virions and by RIPA using [32p]inorganic phosphate-labelled cell lysates, but was not detected by RIPA using [3SS]methionine-labelled cell lysates. NP is also a phosphorylated protein.
The 60K F protein is a glycoprotein, but the incorporation of [14C]glucosamine was very low, partly because there are only three possible glycosylation sites (Merson et al., 1988) . Neither F o nor low Mr protein(s) (F2) could be detected, but we did identify the 60K protein as the F1 protein because MAbs against HN did not precipitate the 60K band and the Mr of the F o protein without saccharides calculated from the deduced amino acid sequence is 60K (Merson et al., 1988) . Furthermore, anti-60K MAbs showed high HLI activity, but no HI or NI activity (Table 2) .
Anti-HN and anti-F MAbs were used to define at least seven and five different antigenic sites on these two hPIV-1 glycoproteins. All the MAbs against HN and the F protein had HLI activity. Of the MAbs against HN, only MAbs belonging to group II had NI activity, indicating that the epitope recognized by the group II MAbs was close to the active site of neuraminidase. Of the MAbs against F protein, those in groups Ia, Ib, Ic and II had high NT titres. Almost all the MAbs to F protein that had NT activity against prototype hPIV-1 also had NT activity against the clinical isolate obtained in Susaka city in 1988 (A1426 strain). This was consistent with the ELISA results indicating that antigenic variation was not found in the F proteins.
Intratypic antigenic analysis of hPIV-1 was performed for the first time using a large collection of MAbs and clinical isolates of hPIV-1 obtained in three geographically distinct regions of Japan between 1959 and 1989. Antigenic diversity between the isolates was found especially in the HN protein, for which there is diversity between those of viruses isolated more than 25 years ago and those isolated relatively recently. The HN proteins of the isolates isolated after 1977 were shown to be antigenically similar. We can not explain the reason for this, but there may have been some antigenic pressure or new types of hPIV-1 may have been introduced. However, it was very interesting that the epitopes recognized by MAbs from groups II, IV, V and VI were conserved in almost all the isolates, and that they all exhibited NT activity against the A1426 strain. These MAbs had characteristic properties: those in group II showed high NI activity; those in groups IV, V and VI had no HI activity. Some of the epitopes identified, which define virus activities, might be conserved owing to restriction to change.
No notable antigenic diversity of the F protein was found. Tsurudome et al. (1989) have reported that the F protein of hPIV-2 isolates is recognized by almost all anti-hPIV-2 F protein MAbs. The difference in the antigenic behaviour of the two glycoproteins remains to be explained.
HPIV-1 has been shown to be antigenically related to SV using antisera (Cook et aL, 1959; Ito et al., 1987) and MAbs against the HN protein of SV (Gorman et aL, 1990) . It was indicated that, in contrast to the high degree of cross-reactivity of polyclonal antibodies, MAbs had limited cross-reactivity with hPIV-1. The present study, using MAbs against the P, NP, HN and F proteins of hPIV-1 and the P, NP, HN, F and M proteins of SV, also revealed limited relationships between hPIV-1 and SV. The common epitopes on the F protein were few, and, interestingly, MAbs against the F protein of SV did not react with clinical hPIV-1 isolates obtained in Susaka and Matsumoto.
Some genes of hPIV-1 have recently been analysed. The HN protein gene was sequenced by Gorman et al. (1990) and Matsuoka et al. (1990) , and they have shown that the HN protein of hPIV-1 is identical in length to that of SV. They also reported that, although the structural elements are conserved, there are marked differences in potential glycosylation sites. This is supported by the respective Mrs, 74K for hPIV-1 HN and 68K for that of SV (Yoshida et al., 1985) . The sequence of the F protein has been determined by Merson et al. (1988) . The F protein is composed of 556 amino acids, and the putative Mr is about 60K without sugar moieties; that of SV is composed of 565 amino acids. The number of potential glycosylation sites is the same for the two viruses. The antigenic and molecular genetic relationships between hPIV-1 and SV are quite similar to those between hPIV-3 and bovine PIV-3. HPIV-3 and bovine PIV-3 are highly similar at the amino acid level Suzu et al., 1987) , but there is significant antigenic diversity between the two viruses (Ray & Compans, 1986; Rydbeck et al., 1987; Klippmark et al., 1990) .
